nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—migraine—Prednisone—prostate cancer	0.483	1	CpDpCtD
Methylergometrine—CYP3A4—prostate cancer	0.135	1	CbGaD
Methylergometrine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0442	0.207	CbGbCtD
Methylergometrine—CYP3A4—Bicalutamide—prostate cancer	0.0232	0.109	CbGbCtD
Methylergometrine—CYP3A4—Estramustine—prostate cancer	0.0216	0.101	CbGbCtD
Methylergometrine—CYP3A4—Abiraterone—prostate cancer	0.0192	0.09	CbGbCtD
Methylergometrine—CYP3A4—Flutamide—prostate cancer	0.0192	0.09	CbGbCtD
Methylergometrine—CYP3A4—Cabazitaxel—prostate cancer	0.0142	0.0666	CbGbCtD
Methylergometrine—CYP3A4—Estrone—prostate cancer	0.0139	0.0651	CbGbCtD
Methylergometrine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0124	0.058	CbGbCtD
Methylergometrine—CYP3A4—Conjugated Estrogens—prostate cancer	0.0091	0.0426	CbGbCtD
Methylergometrine—CYP3A4—Mitoxantrone—prostate cancer	0.00827	0.0387	CbGbCtD
Methylergometrine—CYP3A4—Estradiol—prostate cancer	0.00799	0.0374	CbGbCtD
Methylergometrine—CYP3A4—Prednisone—prostate cancer	0.00687	0.0321	CbGbCtD
Methylergometrine—CYP3A4—Etoposide—prostate cancer	0.00522	0.0244	CbGbCtD
Methylergometrine—CYP3A4—Docetaxel—prostate cancer	0.00477	0.0223	CbGbCtD
Methylergometrine—CYP3A4—Doxorubicin—prostate cancer	0.00356	0.0166	CbGbCtD
Methylergometrine—Haematuria—Mitoxantrone—prostate cancer	0.000274	0.0025	CcSEcCtD
Methylergometrine—Palpitations—Goserelin—prostate cancer	0.000269	0.00245	CcSEcCtD
Methylergometrine—Palpitations—Conjugated Estrogens—prostate cancer	0.000266	0.00242	CcSEcCtD
Methylergometrine—Vomiting—Cabazitaxel—prostate cancer	0.000265	0.00241	CcSEcCtD
Methylergometrine—Convulsion—Goserelin—prostate cancer	0.000264	0.0024	CcSEcCtD
Methylergometrine—Bradycardia—Mitoxantrone—prostate cancer	0.000263	0.00239	CcSEcCtD
Methylergometrine—Hypertension—Goserelin—prostate cancer	0.000263	0.00239	CcSEcCtD
Methylergometrine—Nausea—Degarelix—prostate cancer	0.000262	0.00239	CcSEcCtD
Methylergometrine—Sweating increased—Etoposide—prostate cancer	0.000261	0.00238	CcSEcCtD
Methylergometrine—Convulsion—Conjugated Estrogens—prostate cancer	0.000261	0.00238	CcSEcCtD
Methylergometrine—Headache—Cabazitaxel—prostate cancer	0.000261	0.00237	CcSEcCtD
Methylergometrine—Chest pain—Goserelin—prostate cancer	0.000259	0.00236	CcSEcCtD
Methylergometrine—Tinnitus—Estradiol—prostate cancer	0.000258	0.00235	CcSEcCtD
Methylergometrine—Cardiac disorder—Estradiol—prostate cancer	0.000257	0.00234	CcSEcCtD
Methylergometrine—Thrombophlebitis—Prednisone—prostate cancer	0.000257	0.00234	CcSEcCtD
Methylergometrine—Chest pain—Conjugated Estrogens—prostate cancer	0.000257	0.00234	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Capecitabine—prostate cancer	0.000255	0.00232	CcSEcCtD
Methylergometrine—Anaphylactic shock—Goserelin—prostate cancer	0.000248	0.00226	CcSEcCtD
Methylergometrine—Nausea—Cabazitaxel—prostate cancer	0.000247	0.00225	CcSEcCtD
Methylergometrine—Atrioventricular block—Epirubicin—prostate cancer	0.000247	0.00225	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.000247	0.00225	CcSEcCtD
Methylergometrine—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000246	0.00224	CcSEcCtD
Methylergometrine—Diarrhoea—Bicalutamide—prostate cancer	0.000244	0.00222	CcSEcCtD
Methylergometrine—Nervous system disorder—Goserelin—prostate cancer	0.000243	0.00222	CcSEcCtD
Methylergometrine—Tachycardia—Goserelin—prostate cancer	0.000242	0.00221	CcSEcCtD
Methylergometrine—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000241	0.0022	CcSEcCtD
Methylergometrine—Hyperhidrosis—Goserelin—prostate cancer	0.00024	0.00219	CcSEcCtD
Methylergometrine—Tachycardia—Conjugated Estrogens—prostate cancer	0.00024	0.00219	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Epirubicin—prostate cancer	0.00024	0.00218	CcSEcCtD
Methylergometrine—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000238	0.00217	CcSEcCtD
Methylergometrine—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.000238	0.00216	CcSEcCtD
Methylergometrine—Dizziness—Bicalutamide—prostate cancer	0.000236	0.00215	CcSEcCtD
Methylergometrine—Hypotension—Goserelin—prostate cancer	0.000232	0.00211	CcSEcCtD
Methylergometrine—Muscle spasms—Estradiol—prostate cancer	0.000232	0.00211	CcSEcCtD
Methylergometrine—Hypotension—Conjugated Estrogens—prostate cancer	0.00023	0.00209	CcSEcCtD
Methylergometrine—Atrioventricular block—Doxorubicin—prostate cancer	0.000229	0.00208	CcSEcCtD
Methylergometrine—Vomiting—Bicalutamide—prostate cancer	0.000227	0.00207	CcSEcCtD
Methylergometrine—Rash—Bicalutamide—prostate cancer	0.000225	0.00205	CcSEcCtD
Methylergometrine—Dermatitis—Bicalutamide—prostate cancer	0.000225	0.00205	CcSEcCtD
Methylergometrine—Headache—Bicalutamide—prostate cancer	0.000224	0.00204	CcSEcCtD
Methylergometrine—Paraesthesia—Goserelin—prostate cancer	0.000223	0.00203	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Doxorubicin—prostate cancer	0.000222	0.00202	CcSEcCtD
Methylergometrine—Dyspnoea—Goserelin—prostate cancer	0.000221	0.00202	CcSEcCtD
Methylergometrine—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000221	0.00201	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Epirubicin—prostate cancer	0.00022	0.002	CcSEcCtD
Methylergometrine—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000219	0.002	CcSEcCtD
Methylergometrine—Angina pectoris—Docetaxel—prostate cancer	0.000217	0.00198	CcSEcCtD
Methylergometrine—Ergonovine—CYP3A4—prostate cancer	0.000216	0.297	CrCbGaD
Methylergometrine—Palpitations—Estradiol—prostate cancer	0.000213	0.00194	CcSEcCtD
Methylergometrine—Nausea—Bicalutamide—prostate cancer	0.000212	0.00193	CcSEcCtD
Methylergometrine—Angina pectoris—Capecitabine—prostate cancer	0.00021	0.00191	CcSEcCtD
Methylergometrine—Sweating increased—Capecitabine—prostate cancer	0.00021	0.00191	CcSEcCtD
Methylergometrine—Hypertension—Estradiol—prostate cancer	0.000208	0.0019	CcSEcCtD
Methylergometrine—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000206	0.00188	CcSEcCtD
Methylergometrine—Chest pain—Estradiol—prostate cancer	0.000205	0.00187	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Doxorubicin—prostate cancer	0.000204	0.00186	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Goserelin—prostate cancer	0.000203	0.00185	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000201	0.00183	CcSEcCtD
Methylergometrine—Thrombophlebitis—Epirubicin—prostate cancer	0.000201	0.00183	CcSEcCtD
Methylergometrine—Dizziness—Ethinyl Estradiol—prostate cancer	0.0002	0.00182	CcSEcCtD
Methylergometrine—Cardiac disorder—Etoposide—prostate cancer	0.000199	0.00181	CcSEcCtD
Methylergometrine—Anaphylactic shock—Estradiol—prostate cancer	0.000197	0.00179	CcSEcCtD
Methylergometrine—Abdominal pain—Goserelin—prostate cancer	0.000196	0.00179	CcSEcCtD
Methylergometrine—Convulsion—Mitoxantrone—prostate cancer	0.000195	0.00177	CcSEcCtD
Methylergometrine—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000194	0.00177	CcSEcCtD
Methylergometrine—Hypertension—Mitoxantrone—prostate cancer	0.000194	0.00177	CcSEcCtD
Methylergometrine—Nervous system disorder—Estradiol—prostate cancer	0.000193	0.00176	CcSEcCtD
Methylergometrine—Tachycardia—Estradiol—prostate cancer	0.000192	0.00175	CcSEcCtD
Methylergometrine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000192	0.00175	CcSEcCtD
Methylergometrine—Chest pain—Mitoxantrone—prostate cancer	0.000191	0.00174	CcSEcCtD
Methylergometrine—Hyperhidrosis—Estradiol—prostate cancer	0.00019	0.00173	CcSEcCtD
Methylergometrine—Rash—Ethinyl Estradiol—prostate cancer	0.00019	0.00173	CcSEcCtD
Methylergometrine—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00019	0.00173	CcSEcCtD
Methylergometrine—Headache—Ethinyl Estradiol—prostate cancer	0.000189	0.00172	CcSEcCtD
Methylergometrine—Sweating increased—Prednisone—prostate cancer	0.000187	0.00171	CcSEcCtD
Methylergometrine—Thrombophlebitis—Doxorubicin—prostate cancer	0.000186	0.00169	CcSEcCtD
Methylergometrine—Haematuria—Capecitabine—prostate cancer	0.000184	0.00167	CcSEcCtD
Methylergometrine—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000183	0.00167	CcSEcCtD
Methylergometrine—Muscle spasms—Etoposide—prostate cancer	0.00018	0.00164	CcSEcCtD
Methylergometrine—Nausea—Ethinyl Estradiol—prostate cancer	0.000179	0.00163	CcSEcCtD
Methylergometrine—Tachycardia—Mitoxantrone—prostate cancer	0.000179	0.00163	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Epirubicin—prostate cancer	0.000178	0.00162	CcSEcCtD
Methylergometrine—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000177	0.00161	CcSEcCtD
Methylergometrine—Paraesthesia—Estradiol—prostate cancer	0.000177	0.00161	CcSEcCtD
Methylergometrine—Bradycardia—Capecitabine—prostate cancer	0.000176	0.0016	CcSEcCtD
Methylergometrine—Dyspnoea—Estradiol—prostate cancer	0.000175	0.0016	CcSEcCtD
Methylergometrine—Hypotension—Mitoxantrone—prostate cancer	0.000171	0.00156	CcSEcCtD
Methylergometrine—Diarrhoea—Goserelin—prostate cancer	0.00017	0.00155	CcSEcCtD
Methylergometrine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000168	0.00153	CcSEcCtD
Methylergometrine—Cardiac disorder—Docetaxel—prostate cancer	0.000166	0.00151	CcSEcCtD
Methylergometrine—Paraesthesia—Mitoxantrone—prostate cancer	0.000165	0.0015	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000164	0.0015	CcSEcCtD
Methylergometrine—Dizziness—Goserelin—prostate cancer	0.000164	0.0015	CcSEcCtD
Methylergometrine—Dyspnoea—Mitoxantrone—prostate cancer	0.000164	0.00149	CcSEcCtD
Methylergometrine—Dizziness—Conjugated Estrogens—prostate cancer	0.000163	0.00148	CcSEcCtD
Methylergometrine—Convulsion—Etoposide—prostate cancer	0.000162	0.00147	CcSEcCtD
Methylergometrine—Hypertension—Etoposide—prostate cancer	0.000161	0.00147	CcSEcCtD
Methylergometrine—Tinnitus—Capecitabine—prostate cancer	0.000161	0.00147	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Estradiol—prostate cancer	0.000161	0.00147	CcSEcCtD
Methylergometrine—Cardiac disorder—Capecitabine—prostate cancer	0.00016	0.00146	CcSEcCtD
Methylergometrine—Chest pain—Etoposide—prostate cancer	0.000159	0.00145	CcSEcCtD
Methylergometrine—Vomiting—Goserelin—prostate cancer	0.000158	0.00144	CcSEcCtD
Methylergometrine—Bradycardia—Prednisone—prostate cancer	0.000157	0.00143	CcSEcCtD
Methylergometrine—Rash—Goserelin—prostate cancer	0.000157	0.00143	CcSEcCtD
Methylergometrine—Dermatitis—Goserelin—prostate cancer	0.000156	0.00142	CcSEcCtD
Methylergometrine—Vomiting—Conjugated Estrogens—prostate cancer	0.000156	0.00142	CcSEcCtD
Methylergometrine—Abdominal pain—Estradiol—prostate cancer	0.000156	0.00142	CcSEcCtD
Methylergometrine—Headache—Goserelin—prostate cancer	0.000156	0.00142	CcSEcCtD
Methylergometrine—Rash—Conjugated Estrogens—prostate cancer	0.000155	0.00141	CcSEcCtD
Methylergometrine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000155	0.00141	CcSEcCtD
Methylergometrine—Headache—Conjugated Estrogens—prostate cancer	0.000154	0.0014	CcSEcCtD
Methylergometrine—Hallucination—Prednisone—prostate cancer	0.000153	0.00139	CcSEcCtD
Methylergometrine—Anaphylactic shock—Etoposide—prostate cancer	0.000153	0.00139	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.00015	0.00137	CcSEcCtD
Methylergometrine—Muscle spasms—Docetaxel—prostate cancer	0.000149	0.00136	CcSEcCtD
Methylergometrine—Tachycardia—Etoposide—prostate cancer	0.000149	0.00136	CcSEcCtD
Methylergometrine—Nausea—Goserelin—prostate cancer	0.000147	0.00134	CcSEcCtD
Methylergometrine—Hyperhidrosis—Etoposide—prostate cancer	0.000147	0.00134	CcSEcCtD
Methylergometrine—Angina pectoris—Epirubicin—prostate cancer	0.000146	0.00133	CcSEcCtD
Methylergometrine—Nausea—Conjugated Estrogens—prostate cancer	0.000146	0.00133	CcSEcCtD
Methylergometrine—Pergolide—CYP3A4—prostate cancer	0.000146	0.201	CrCbGaD
Methylergometrine—Abdominal pain—Mitoxantrone—prostate cancer	0.000145	0.00132	CcSEcCtD
Methylergometrine—Muscle spasms—Capecitabine—prostate cancer	0.000145	0.00132	CcSEcCtD
Methylergometrine—Hypotension—Etoposide—prostate cancer	0.000143	0.0013	CcSEcCtD
Methylergometrine—Palpitations—Docetaxel—prostate cancer	0.000137	0.00125	CcSEcCtD
Methylergometrine—Paraesthesia—Etoposide—prostate cancer	0.000137	0.00125	CcSEcCtD
Methylergometrine—Dyspnoea—Etoposide—prostate cancer	0.000136	0.00124	CcSEcCtD
Methylergometrine—Angina pectoris—Doxorubicin—prostate cancer	0.000136	0.00123	CcSEcCtD
Methylergometrine—Diarrhoea—Estradiol—prostate cancer	0.000135	0.00123	CcSEcCtD
Methylergometrine—Convulsion—Docetaxel—prostate cancer	0.000135	0.00123	CcSEcCtD
Methylergometrine—Hypertension—Docetaxel—prostate cancer	0.000134	0.00122	CcSEcCtD
Methylergometrine—Palpitations—Capecitabine—prostate cancer	0.000133	0.00121	CcSEcCtD
Methylergometrine—Chest pain—Docetaxel—prostate cancer	0.000132	0.0012	CcSEcCtD
Methylergometrine—Dizziness—Estradiol—prostate cancer	0.00013	0.00119	CcSEcCtD
Methylergometrine—Hypertension—Capecitabine—prostate cancer	0.00013	0.00118	CcSEcCtD
Methylergometrine—Chest pain—Capecitabine—prostate cancer	0.000128	0.00117	CcSEcCtD
Methylergometrine—Haematuria—Epirubicin—prostate cancer	0.000128	0.00116	CcSEcCtD
Methylergometrine—Anaphylactic shock—Docetaxel—prostate cancer	0.000127	0.00115	CcSEcCtD
Methylergometrine—Lisuride—CYP3A4—prostate cancer	0.000126	0.174	CrCbGaD
Methylergometrine—Diarrhoea—Mitoxantrone—prostate cancer	0.000125	0.00114	CcSEcCtD
Methylergometrine—Vomiting—Estradiol—prostate cancer	0.000125	0.00114	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Etoposide—prostate cancer	0.000125	0.00114	CcSEcCtD
Methylergometrine—Nervous system disorder—Docetaxel—prostate cancer	0.000124	0.00113	CcSEcCtD
Methylergometrine—Rash—Estradiol—prostate cancer	0.000124	0.00113	CcSEcCtD
Methylergometrine—Dermatitis—Estradiol—prostate cancer	0.000124	0.00113	CcSEcCtD
Methylergometrine—Tachycardia—Docetaxel—prostate cancer	0.000124	0.00113	CcSEcCtD
Methylergometrine—Headache—Estradiol—prostate cancer	0.000123	0.00112	CcSEcCtD
Methylergometrine—Bradycardia—Epirubicin—prostate cancer	0.000123	0.00112	CcSEcCtD
Methylergometrine—Ergotamine—CYP3A4—prostate cancer	0.000121	0.167	CrCbGaD
Methylergometrine—Abdominal pain—Etoposide—prostate cancer	0.000121	0.0011	CcSEcCtD
Methylergometrine—Nervous system disorder—Capecitabine—prostate cancer	0.00012	0.0011	CcSEcCtD
Methylergometrine—Tachycardia—Capecitabine—prostate cancer	0.00012	0.00109	CcSEcCtD
Methylergometrine—Hyperhidrosis—Capecitabine—prostate cancer	0.000119	0.00108	CcSEcCtD
Methylergometrine—Hypotension—Docetaxel—prostate cancer	0.000118	0.00108	CcSEcCtD
Methylergometrine—Haematuria—Doxorubicin—prostate cancer	0.000118	0.00108	CcSEcCtD
Methylergometrine—Bromocriptine—CYP3A4—prostate cancer	0.000117	0.161	CrCbGaD
Methylergometrine—Nausea—Estradiol—prostate cancer	0.000117	0.00106	CcSEcCtD
Methylergometrine—Vomiting—Mitoxantrone—prostate cancer	0.000117	0.00106	CcSEcCtD
Methylergometrine—Convulsion—Prednisone—prostate cancer	0.000116	0.00106	CcSEcCtD
Methylergometrine—Hypertension—Prednisone—prostate cancer	0.000116	0.00105	CcSEcCtD
Methylergometrine—Rash—Mitoxantrone—prostate cancer	0.000116	0.00105	CcSEcCtD
Methylergometrine—Dermatitis—Mitoxantrone—prostate cancer	0.000116	0.00105	CcSEcCtD
Methylergometrine—Headache—Mitoxantrone—prostate cancer	0.000115	0.00105	CcSEcCtD
Methylergometrine—Hypotension—Capecitabine—prostate cancer	0.000115	0.00104	CcSEcCtD
Methylergometrine—Paraesthesia—Docetaxel—prostate cancer	0.000114	0.00104	CcSEcCtD
Methylergometrine—Bradycardia—Doxorubicin—prostate cancer	0.000113	0.00103	CcSEcCtD
Methylergometrine—Dyspnoea—Docetaxel—prostate cancer	0.000113	0.00103	CcSEcCtD
Methylergometrine—Tinnitus—Epirubicin—prostate cancer	0.000112	0.00102	CcSEcCtD
Methylergometrine—Cardiac disorder—Epirubicin—prostate cancer	0.000112	0.00102	CcSEcCtD
Methylergometrine—Paraesthesia—Capecitabine—prostate cancer	0.00011	0.001	CcSEcCtD
Methylergometrine—Dyspnoea—Capecitabine—prostate cancer	0.000109	0.000996	CcSEcCtD
Methylergometrine—Anaphylactic shock—Prednisone—prostate cancer	0.000109	0.000996	CcSEcCtD
Methylergometrine—Nausea—Mitoxantrone—prostate cancer	0.000109	0.000992	CcSEcCtD
Methylergometrine—Nervous system disorder—Prednisone—prostate cancer	0.000107	0.000976	CcSEcCtD
Methylergometrine—Tachycardia—Prednisone—prostate cancer	0.000107	0.000972	CcSEcCtD
Methylergometrine—Hyperhidrosis—Prednisone—prostate cancer	0.000106	0.000962	CcSEcCtD
Methylergometrine—Diarrhoea—Etoposide—prostate cancer	0.000104	0.00095	CcSEcCtD
Methylergometrine—Tinnitus—Doxorubicin—prostate cancer	0.000104	0.000945	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Docetaxel—prostate cancer	0.000104	0.000944	CcSEcCtD
Methylergometrine—Cardiac disorder—Doxorubicin—prostate cancer	0.000103	0.000941	CcSEcCtD
Methylergometrine—Dizziness—Etoposide—prostate cancer	0.000101	0.000919	CcSEcCtD
Methylergometrine—Muscle spasms—Epirubicin—prostate cancer	0.000101	0.000917	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Capecitabine—prostate cancer	0.0001	0.000914	CcSEcCtD
Methylergometrine—Abdominal pain—Docetaxel—prostate cancer	0.0001	0.000913	CcSEcCtD
Methylergometrine—Paraesthesia—Prednisone—prostate cancer	9.82e-05	0.000894	CcSEcCtD
Methylergometrine—Abdominal pain—Capecitabine—prostate cancer	9.7e-05	0.000884	CcSEcCtD
Methylergometrine—Vomiting—Etoposide—prostate cancer	9.7e-05	0.000883	CcSEcCtD
Methylergometrine—Rash—Etoposide—prostate cancer	9.62e-05	0.000876	CcSEcCtD
Methylergometrine—Dermatitis—Etoposide—prostate cancer	9.61e-05	0.000875	CcSEcCtD
Methylergometrine—Headache—Etoposide—prostate cancer	9.56e-05	0.00087	CcSEcCtD
Methylergometrine—Muscle spasms—Doxorubicin—prostate cancer	9.32e-05	0.000849	CcSEcCtD
Methylergometrine—Palpitations—Epirubicin—prostate cancer	9.26e-05	0.000843	CcSEcCtD
Methylergometrine—Convulsion—Epirubicin—prostate cancer	9.08e-05	0.000827	CcSEcCtD
Methylergometrine—Nausea—Etoposide—prostate cancer	9.06e-05	0.000825	CcSEcCtD
Methylergometrine—Hypertension—Epirubicin—prostate cancer	9.05e-05	0.000824	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Prednisone—prostate cancer	8.94e-05	0.000814	CcSEcCtD
Methylergometrine—Chest pain—Epirubicin—prostate cancer	8.92e-05	0.000812	CcSEcCtD
Methylergometrine—Diarrhoea—Docetaxel—prostate cancer	8.67e-05	0.00079	CcSEcCtD
Methylergometrine—Abdominal pain—Prednisone—prostate cancer	8.64e-05	0.000787	CcSEcCtD
Methylergometrine—Palpitations—Doxorubicin—prostate cancer	8.57e-05	0.00078	CcSEcCtD
Methylergometrine—Anaphylactic shock—Epirubicin—prostate cancer	8.55e-05	0.000779	CcSEcCtD
Methylergometrine—Convulsion—Doxorubicin—prostate cancer	8.4e-05	0.000765	CcSEcCtD
Methylergometrine—Diarrhoea—Capecitabine—prostate cancer	8.4e-05	0.000765	CcSEcCtD
Methylergometrine—Nervous system disorder—Epirubicin—prostate cancer	8.39e-05	0.000764	CcSEcCtD
Methylergometrine—Dizziness—Docetaxel—prostate cancer	8.38e-05	0.000763	CcSEcCtD
Methylergometrine—Hypertension—Doxorubicin—prostate cancer	8.37e-05	0.000762	CcSEcCtD
Methylergometrine—Tachycardia—Epirubicin—prostate cancer	8.35e-05	0.00076	CcSEcCtD
Methylergometrine—Hyperhidrosis—Epirubicin—prostate cancer	8.27e-05	0.000753	CcSEcCtD
Methylergometrine—Chest pain—Doxorubicin—prostate cancer	8.25e-05	0.000752	CcSEcCtD
Methylergometrine—Dizziness—Capecitabine—prostate cancer	8.12e-05	0.000739	CcSEcCtD
Methylergometrine—Vomiting—Docetaxel—prostate cancer	8.06e-05	0.000734	CcSEcCtD
Methylergometrine—Rash—Docetaxel—prostate cancer	7.99e-05	0.000728	CcSEcCtD
Methylergometrine—Hypotension—Epirubicin—prostate cancer	7.99e-05	0.000728	CcSEcCtD
Methylergometrine—Dermatitis—Docetaxel—prostate cancer	7.99e-05	0.000727	CcSEcCtD
Methylergometrine—Headache—Docetaxel—prostate cancer	7.94e-05	0.000723	CcSEcCtD
Methylergometrine—Anaphylactic shock—Doxorubicin—prostate cancer	7.91e-05	0.00072	CcSEcCtD
Methylergometrine—Vomiting—Capecitabine—prostate cancer	7.8e-05	0.000711	CcSEcCtD
Methylergometrine—Nervous system disorder—Doxorubicin—prostate cancer	7.76e-05	0.000707	CcSEcCtD
Methylergometrine—Rash—Capecitabine—prostate cancer	7.74e-05	0.000705	CcSEcCtD
Methylergometrine—Dermatitis—Capecitabine—prostate cancer	7.73e-05	0.000704	CcSEcCtD
Methylergometrine—Tachycardia—Doxorubicin—prostate cancer	7.72e-05	0.000703	CcSEcCtD
Methylergometrine—Headache—Capecitabine—prostate cancer	7.69e-05	0.0007	CcSEcCtD
Methylergometrine—Paraesthesia—Epirubicin—prostate cancer	7.68e-05	0.000699	CcSEcCtD
Methylergometrine—Hyperhidrosis—Doxorubicin—prostate cancer	7.65e-05	0.000696	CcSEcCtD
Methylergometrine—Dyspnoea—Epirubicin—prostate cancer	7.62e-05	0.000694	CcSEcCtD
Methylergometrine—Nausea—Docetaxel—prostate cancer	7.53e-05	0.000686	CcSEcCtD
Methylergometrine—Diarrhoea—Prednisone—prostate cancer	7.48e-05	0.000681	CcSEcCtD
Methylergometrine—Hypotension—Doxorubicin—prostate cancer	7.39e-05	0.000673	CcSEcCtD
Methylergometrine—Nausea—Capecitabine—prostate cancer	7.29e-05	0.000664	CcSEcCtD
Methylergometrine—Dizziness—Prednisone—prostate cancer	7.23e-05	0.000658	CcSEcCtD
Methylergometrine—Paraesthesia—Doxorubicin—prostate cancer	7.11e-05	0.000647	CcSEcCtD
Methylergometrine—Dyspnoea—Doxorubicin—prostate cancer	7.05e-05	0.000642	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Epirubicin—prostate cancer	6.99e-05	0.000637	CcSEcCtD
Methylergometrine—Vomiting—Prednisone—prostate cancer	6.95e-05	0.000633	CcSEcCtD
Methylergometrine—Rash—Prednisone—prostate cancer	6.89e-05	0.000628	CcSEcCtD
Methylergometrine—Dermatitis—Prednisone—prostate cancer	6.89e-05	0.000627	CcSEcCtD
Methylergometrine—Headache—Prednisone—prostate cancer	6.85e-05	0.000624	CcSEcCtD
Methylergometrine—Abdominal pain—Epirubicin—prostate cancer	6.76e-05	0.000616	CcSEcCtD
Methylergometrine—Nausea—Prednisone—prostate cancer	6.49e-05	0.000591	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Doxorubicin—prostate cancer	6.47e-05	0.000589	CcSEcCtD
Methylergometrine—Abdominal pain—Doxorubicin—prostate cancer	6.25e-05	0.00057	CcSEcCtD
Methylergometrine—Diarrhoea—Epirubicin—prostate cancer	5.85e-05	0.000533	CcSEcCtD
Methylergometrine—Dizziness—Epirubicin—prostate cancer	5.65e-05	0.000515	CcSEcCtD
Methylergometrine—Vomiting—Epirubicin—prostate cancer	5.44e-05	0.000495	CcSEcCtD
Methylergometrine—Diarrhoea—Doxorubicin—prostate cancer	5.41e-05	0.000493	CcSEcCtD
Methylergometrine—Rash—Epirubicin—prostate cancer	5.39e-05	0.000491	CcSEcCtD
Methylergometrine—Dermatitis—Epirubicin—prostate cancer	5.39e-05	0.00049	CcSEcCtD
Methylergometrine—Headache—Epirubicin—prostate cancer	5.36e-05	0.000488	CcSEcCtD
Methylergometrine—Dizziness—Doxorubicin—prostate cancer	5.23e-05	0.000476	CcSEcCtD
Methylergometrine—Nausea—Epirubicin—prostate cancer	5.08e-05	0.000463	CcSEcCtD
Methylergometrine—Vomiting—Doxorubicin—prostate cancer	5.03e-05	0.000458	CcSEcCtD
Methylergometrine—Rash—Doxorubicin—prostate cancer	4.99e-05	0.000454	CcSEcCtD
Methylergometrine—Dermatitis—Doxorubicin—prostate cancer	4.98e-05	0.000454	CcSEcCtD
Methylergometrine—Headache—Doxorubicin—prostate cancer	4.96e-05	0.000451	CcSEcCtD
Methylergometrine—Nausea—Doxorubicin—prostate cancer	4.7e-05	0.000428	CcSEcCtD
Methylergometrine—DRD1—Signaling Pathways—GSK3B—prostate cancer	4.82e-06	8.45e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTA1—prostate cancer	4.77e-06	8.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ITGB3—prostate cancer	4.77e-06	8.35e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—LEP—prostate cancer	4.76e-06	8.35e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—INS—prostate cancer	4.76e-06	8.33e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CAV1—prostate cancer	4.72e-06	8.27e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTO1—prostate cancer	4.72e-06	8.27e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.72e-06	8.27e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NAT2—prostate cancer	4.72e-06	8.27e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAP2K1—prostate cancer	4.72e-06	8.26e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MYC—prostate cancer	4.7e-06	8.24e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TGFB1—prostate cancer	4.69e-06	8.22e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CD—prostate cancer	4.69e-06	8.21e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KDR—prostate cancer	4.67e-06	8.18e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CREBBP—prostate cancer	4.66e-06	8.16e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CXCL8—prostate cancer	4.65e-06	8.15e-05	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—PIK3CA—prostate cancer	4.64e-06	8.13e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SERPINE1—prostate cancer	4.63e-06	8.12e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ERBB3—prostate cancer	4.62e-06	8.1e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—FGFR2—prostate cancer	4.62e-06	8.09e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—KRAS—prostate cancer	4.61e-06	8.07e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IGF1—prostate cancer	4.6e-06	8.06e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—EGFR—prostate cancer	4.6e-06	8.06e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—KRAS—prostate cancer	4.59e-06	8.04e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—EGFR—prostate cancer	4.58e-06	8.02e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ESR1—prostate cancer	4.55e-06	7.97e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LRP2—prostate cancer	4.52e-06	7.93e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PLCB2—prostate cancer	4.52e-06	7.93e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.52e-06	7.93e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—FGF2—prostate cancer	4.49e-06	7.86e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL2—prostate cancer	4.45e-06	7.79e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAP2K1—prostate cancer	4.45e-06	7.79e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—BAD—prostate cancer	4.44e-06	7.78e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—P4HB—prostate cancer	4.44e-06	7.77e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TERT—prostate cancer	4.43e-06	7.76e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NOS3—prostate cancer	4.42e-06	7.75e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CD—prostate cancer	4.42e-06	7.74e-05	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PIK3CA—prostate cancer	4.38e-06	7.67e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SERPINE1—prostate cancer	4.37e-06	7.66e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—KRAS—prostate cancer	4.35e-06	7.61e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—KRAS—prostate cancer	4.33e-06	7.58e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.32e-06	7.56e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—JAK2—prostate cancer	4.3e-06	7.53e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CG—prostate cancer	4.3e-06	7.53e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APC—prostate cancer	4.3e-06	7.53e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGF—prostate cancer	4.25e-06	7.45e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IRS1—prostate cancer	4.25e-06	7.45e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HIF1A—prostate cancer	4.24e-06	7.42e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PIK3CA—prostate cancer	4.23e-06	7.41e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—FGF2—prostate cancer	4.23e-06	7.41e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PIK3CA—prostate cancer	4.21e-06	7.38e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.21e-06	7.37e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MDM2—prostate cancer	4.2e-06	7.35e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NOS3—prostate cancer	4.17e-06	7.31e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MED12—prostate cancer	4.14e-06	7.25e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ERBB2—prostate cancer	4.14e-06	7.25e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—LEP—prostate cancer	4.14e-06	7.25e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—GSK3B—prostate cancer	4.13e-06	7.23e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GNG5—prostate cancer	4.11e-06	7.19e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CAV1—prostate cancer	4.1e-06	7.18e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TP53—prostate cancer	4.09e-06	7.17e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CB—prostate cancer	4.08e-06	7.15e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—INS—prostate cancer	4.07e-06	7.13e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—JAK2—prostate cancer	4.06e-06	7.1e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KDR—prostate cancer	4.05e-06	7.1e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PIK3CA—prostate cancer	3.99e-06	6.99e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CREBBP—prostate cancer	3.99e-06	6.98e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PIK3CA—prostate cancer	3.97e-06	6.96e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MDM2—prostate cancer	3.96e-06	6.93e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOA3—prostate cancer	3.96e-06	6.93e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ESR1—prostate cancer	3.95e-06	6.92e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IGF1—prostate cancer	3.94e-06	6.9e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CXCL8—prostate cancer	3.92e-06	6.87e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—EGFR—prostate cancer	3.92e-06	6.86e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ERBB2—prostate cancer	3.9e-06	6.84e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TP53—prostate cancer	3.86e-06	6.77e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—BAD—prostate cancer	3.86e-06	6.75e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CB—prostate cancer	3.85e-06	6.75e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CDKN1B—prostate cancer	3.83e-06	6.71e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAP2K1—prostate cancer	3.81e-06	6.67e-05	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—prostate cancer	3.79e-06	6.64e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CD—prostate cancer	3.78e-06	6.62e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HPGDS—prostate cancer	3.77e-06	6.61e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CASP3—prostate cancer	3.76e-06	6.58e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL2—prostate cancer	3.75e-06	6.57e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.75e-06	6.57e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL6—prostate cancer	3.75e-06	6.57e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CA—prostate cancer	3.74e-06	6.56e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SERPINE1—prostate cancer	3.74e-06	6.55e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APC—prostate cancer	3.73e-06	6.54e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	3.73e-06	6.54e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL6—prostate cancer	3.73e-06	6.54e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CXCL8—prostate cancer	3.7e-06	6.48e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—KRAS—prostate cancer	3.7e-06	6.48e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGF—prostate cancer	3.69e-06	6.47e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IRS1—prostate cancer	3.69e-06	6.47e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ACHE—prostate cancer	3.66e-06	6.41e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTT1—prostate cancer	3.66e-06	6.41e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCND1—prostate cancer	3.66e-06	6.4e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CTNNB1—prostate cancer	3.62e-06	6.34e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—FGF2—prostate cancer	3.62e-06	6.34e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.62e-06	6.34e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CDKN1B—prostate cancer	3.61e-06	6.33e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GSK3B—prostate cancer	3.58e-06	6.28e-05	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—prostate cancer	3.58e-06	6.26e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NOS3—prostate cancer	3.57e-06	6.25e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MMP9—prostate cancer	3.55e-06	6.22e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CASP3—prostate cancer	3.54e-06	6.21e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL2—prostate cancer	3.54e-06	6.2e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CDKN1A—prostate cancer	3.54e-06	6.2e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL6—prostate cancer	3.54e-06	6.19e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—INS—prostate cancer	3.53e-06	6.19e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTEN—prostate cancer	3.53e-06	6.18e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL6—prostate cancer	3.52e-06	6.16e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.52e-06	6.16e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PRKACB—prostate cancer	3.5e-06	6.13e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—JAK2—prostate cancer	3.47e-06	6.08e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.46e-06	6.07e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CREBBP—prostate cancer	3.46e-06	6.06e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—prostate cancer	3.46e-06	6.06e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCND1—prostate cancer	3.45e-06	6.04e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—prostate cancer	3.44e-06	6.03e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IGF1—prostate cancer	3.42e-06	5.99e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CTNNB1—prostate cancer	3.41e-06	5.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—EGFR—prostate cancer	3.4e-06	5.96e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CA—prostate cancer	3.4e-06	5.96e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MDM2—prostate cancer	3.39e-06	5.93e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EP300—prostate cancer	3.37e-06	5.9e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MMP9—prostate cancer	3.35e-06	5.86e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ERBB2—prostate cancer	3.34e-06	5.85e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CDKN1A—prostate cancer	3.34e-06	5.84e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTEN—prostate cancer	3.33e-06	5.83e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	3.3e-06	5.79e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOA2—prostate cancer	3.3e-06	5.78e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	3.29e-06	5.77e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	3.28e-06	5.75e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SRC—prostate cancer	3.27e-06	5.73e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—prostate cancer	3.26e-06	5.71e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	3.25e-06	5.7e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—prostate cancer	3.25e-06	5.69e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	3.25e-06	5.69e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—KRAS—prostate cancer	3.21e-06	5.63e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—prostate cancer	3.19e-06	5.58e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EP300—prostate cancer	3.17e-06	5.56e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CXCL8—prostate cancer	3.17e-06	5.55e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STAT3—prostate cancer	3.16e-06	5.53e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.15e-06	5.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—FGF2—prostate cancer	3.14e-06	5.51e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOS3—prostate cancer	3.1e-06	5.43e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	3.09e-06	5.42e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SRC—prostate cancer	3.09e-06	5.41e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.08e-06	5.39e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	3.06e-06	5.36e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NQO1—prostate cancer	3.04e-06	5.33e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CASP3—prostate cancer	3.03e-06	5.31e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL2—prostate cancer	3.03e-06	5.3e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—JAK2—prostate cancer	3.01e-06	5.28e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL6—prostate cancer	3.01e-06	5.27e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—prostate cancer	3.01e-06	5.27e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TH—prostate cancer	3e-06	5.25e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STAT3—prostate cancer	2.98e-06	5.21e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	2.95e-06	5.17e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCND1—prostate cancer	2.95e-06	5.17e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MDM2—prostate cancer	2.94e-06	5.15e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MYC—prostate cancer	2.93e-06	5.14e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TGFB1—prostate cancer	2.93e-06	5.12e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	2.92e-06	5.12e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.92e-06	5.11e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ERBB2—prostate cancer	2.9e-06	5.08e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EGFR—prostate cancer	2.87e-06	5.02e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP9—prostate cancer	2.86e-06	5.02e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	2.86e-06	5.01e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	2.85e-06	5e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTEN—prostate cancer	2.85e-06	4.99e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GGT1—prostate cancer	2.82e-06	4.95e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOA1—prostate cancer	2.78e-06	4.87e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	2.78e-06	4.87e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MYC—prostate cancer	2.77e-06	4.84e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TGFB1—prostate cancer	2.76e-06	4.83e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CXCL8—prostate cancer	2.75e-06	4.82e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.74e-06	4.8e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EP300—prostate cancer	2.72e-06	4.76e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—KRAS—prostate cancer	2.71e-06	4.75e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGFR—prostate cancer	2.71e-06	4.74e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	2.69e-06	4.7e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	2.66e-06	4.65e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—RXRA—prostate cancer	2.65e-06	4.63e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SRC—prostate cancer	2.64e-06	4.63e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CASP3—prostate cancer	2.63e-06	4.61e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL2—prostate cancer	2.63e-06	4.6e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL6—prostate cancer	2.61e-06	4.58e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	2.57e-06	4.5e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCND1—prostate cancer	2.56e-06	4.49e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—KRAS—prostate cancer	2.56e-06	4.48e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—COMT—prostate cancer	2.55e-06	4.46e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STAT3—prostate cancer	2.55e-06	4.46e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	2.54e-06	4.44e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTP1—prostate cancer	2.54e-06	4.44e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ITPR1—prostate cancer	2.5e-06	4.37e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	2.49e-06	4.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.49e-06	4.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.48e-06	4.34e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.47e-06	4.33e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.41e-06	4.23e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TP53—prostate cancer	2.41e-06	4.22e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MYC—prostate cancer	2.37e-06	4.14e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.36e-06	4.13e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TYMS—prostate cancer	2.36e-06	4.13e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EP300—prostate cancer	2.36e-06	4.13e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CA—prostate cancer	2.35e-06	4.11e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTM1—prostate cancer	2.33e-06	4.08e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGFR—prostate cancer	2.31e-06	4.05e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SRC—prostate cancer	2.29e-06	4.02e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LPL—prostate cancer	2.29e-06	4.01e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TP53—prostate cancer	2.27e-06	3.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	2.23e-06	3.91e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STAT3—prostate cancer	2.21e-06	3.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.21e-06	3.87e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6—prostate cancer	2.2e-06	3.86e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ERCC2—prostate cancer	2.19e-06	3.84e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KRAS—prostate cancer	2.19e-06	3.83e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6—prostate cancer	2.08e-06	3.64e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MTHFR—prostate cancer	2.06e-06	3.61e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MYC—prostate cancer	2.05e-06	3.6e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	2.05e-06	3.59e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—prostate cancer	2.03e-06	3.56e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARA—prostate cancer	2.02e-06	3.54e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGFR—prostate cancer	2.01e-06	3.52e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	2.01e-06	3.52e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TP53—prostate cancer	1.94e-06	3.4e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—prostate cancer	1.92e-06	3.36e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CAV1—prostate cancer	1.9e-06	3.33e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.9e-06	3.33e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6—prostate cancer	1.78e-06	3.12e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.74e-06	3.06e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.73e-06	3.03e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TP53—prostate cancer	1.69e-06	2.96e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.64e-06	2.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—INS—prostate cancer	1.64e-06	2.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.6e-06	2.81e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6—prostate cancer	1.54e-06	2.71e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.52e-06	2.67e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NOS3—prostate cancer	1.44e-06	2.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.42e-06	2.5e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.33e-06	2.32e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.31e-06	2.3e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTEN—prostate cancer	1.15e-06	2.01e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—EP300—prostate cancer	1.09e-06	1.91e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.08e-07	1.42e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—prostate cancer	6.6e-07	1.16e-05	CbGpPWpGaD
